Minimal Residual Disease in Acute Myeloid Leukemia

被引：12

作者：

Gomez-Arteaga, Alexandra ^{[1
]}

Guzman, Monica L. ^{[1
]}

机构：

[1] New York Presbyterian Hosp, Weill Cornell Med, Div Hematol & Oncol, Dept Med, New York, NY 10065 USA

来源：

BIOLOGICAL MECHANISMS OF MINIMAL RESIDUAL DISEASE AND SYSTEMIC CANCER | 2018年 / 1100卷

关键词：

Minimal residual disease; MRD; Acute myeloid leukemia; Leukemia stem cells; Leukemia-associated immunophenotypes; FLT3; Runx1; DNMT3A; IDH1; IDH2; STEM-CELL TRANSPLANTATION; FLOW-CYTOMETRY; CONSOLIDATION THERAPY; RISK STRATIFICATION; CLONAL EVOLUTION; PROGNOSTIC VALUE; PREDICT RELAPSE; DIGITAL PCR; AML; TIME;

D O I：

10.1007/978-3-319-97746-1_7

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Monitoring measurable (minimal) residual disease (MRD) in acute myeloid leukemia (AML) has greatly increased our ability to assess chemosensisitivity to treatment as well as the duration of treatment responses. There is strong evidence to support its prognostic value for long-term outcomes at different time points and across assays and targets. It's role as a surrogate endpoint to define risk-adapted strategies is still under evaluation. In this chapter, we will discuss the definition of MRD in AML, the potential contribution of leukemia stem cells (LSCs) to MRD and we will review all the current approaches to assess residual disease including the 2018 European Leukemia Network (ELN) working group recommendations for MRD standardization in AML. In addition, a summary of MRD studies associated to prognosis will be described.

引用

页码：111 / 125

页数：15

共 76 条

[1]

[Anonymous], 2017, BLOOD S1

[2] HAEMATOLOGICAL CANCER The rule of three in AML induction-is cladribine the answer? [J].

Appelbaum, Frederick R. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (07) :376-377

[3] Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? [J].

Araki, Daisuke ;

Wood, Brent L. ;

Othus, Megan ;

Radich, Jerald P. ;

Halpern, Anna B. ;

Zhou, Yi ;

Mielcarek, Marco ;

Estey, Elihu H. ;

Appelbaum, Frederick R. ;

Walter, Roland B. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04) :329-+

[4] Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group [J].

Balsat, Marie ;

Renneville, Aline ;

Thomas, Xavier ;

de Botton, Stephane ;

Caillot, Denis ;

Marceau, Alice ;

Lemasle, Emilie ;

Marolleau, Jean-Pierre ;

Nibourel, Olivier ;

Berthon, Celine ;

Raffoux, Emmanuel ;

Pigneux, Arnaud ;

Rodriguez, Celine ;

Vey, Norbert ;

Cayuela, Jean-Michel ;

Hayette, Sandrine ;

Braun, Thorsten ;

Coude, Marie Magdeleine ;

Terre, Christine ;

Celli-Lebras, Karine ;

Dombret, Herve ;

Preudhomme, Claude ;

Boissel, Nicolas .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) :185-+

[5] Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy [J].

Behbehani, Gregory K. ;

Samusik, Nikolay ;

Bjornson, Zach B. ;

Fantl, Wendy J. ;

Medeiros, Bruno C. ;

Nolan, Garry P. .

CANCER DISCOVERY, 2015, 5 (09) :988-1003

[6] Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].

Bonnet, D ;

Dick, JE .

NATURE MEDICINE, 1997, 3 (07) :730-737

[7] Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia [J].

Bradbury, C. ;

Houlton, A. E. ;

Akiki, S. ;

Gregg, R. ;

Rindl, M. ;

Khan, J. ;

Ward, J. ;

Khan, N. ;

Griffiths, M. ;

Nagra, S. ;

Hills, R. ;

Burnett, A. ;

Russell, N. ;

Vyas, P. ;

Grimwade, D. ;

Craddock, C. ;

Freeman, S. D. .

LEUKEMIA, 2015, 29 (04) :988-991

[8] Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation [J].

Brambati, Chiara ;

Galbiati, Silvia ;

Xue, Elisabetta ;

Toffalori, Cristina ;

Crucitti, Lara ;

Greco, Raffaella ;

Sala, Elisa ;

Crippa, Alessandra ;

Chiesa, Lorenza ;

Soriani, Nadia ;

Mazzi, Benedetta ;

Tresoldi, Cristina ;

Stanghellini, Maria Teresa Lupo ;

Peccatori, Jacopo ;

Carrabba, Matteo G. ;

Bernardi, Massimo ;

Ferrari, Maurizio ;

Lampasona, Vito ;

Ciceri, Fabio ;

Vago, Luca .

HAEMATOLOGICA, 2016, 101 (04)

[9] The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia [J].

Buccisano, F. ;

Maurillo, L. ;

Gattei, V. ;

Del Poeta, G. ;

Del Principe, M. I. ;

Cox, M. C. ;

Panetta, P. ;

Consalvo, M. Irno ;

Mazzone, C. ;

Neri, B. ;

Ottaviani, L. ;

Fraboni, D. ;

Tamburini, A. ;

Lo-Coco, F. ;

Amadori, S. ;

Venditti, A. .

LEUKEMIA, 2006, 20 (10) :1783-1789

[10] Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis [J].

Buckley, Sarah A. ;

Wood, Brent L. ;

Othus, Megan ;

Hourigan, Christopher S. ;

Ustun, Celalettin ;

Linden, Michael A. ;

DeFor, Todd E. ;

Malagola, Michele ;

Anthias, Chloe ;

Valkova, Veronika ;

Kanakry, Christopher G. ;

Gruhn, Bernd ;

Buccisano, Francesco ;

Devine, Beth ;

Walter, Roland B. .

HAEMATOLOGICA, 2017, 102 (05) :865-873

← 1 2 3 4 5 6 7 8 →